Literature DB >> 25591841

Para-aortic nodal metastases in cervical cancer: a blind spot in the International Federation of Gynecology and Obstetrics staging system: current diagnosis and management.

Lindsay Hwang1, April Bailey, Jayanthi Lea, Kevin Albuquerque.   

Abstract

In cervical cancer, para-aortic nodal (PALN) metastases at presentation is a strong indicator of poor prognosis. Despite this, International Federation of Gynecology and Obstetrics staging system does not require evaluation of lymph node involvement and does not incorporate clinically detected PALN into the staging system. In the USA, despite screening, a significant number of women still present at an advanced stage often with nodal metastases. While the presence of PALN metastases often indicates occult systemic disease, it is possible with modern therapies to provide long-term control of disease in a percentage of patients. We review the epidemiology, diagnosis and treatment of PALN metastases in cervical cancer outlining advances in modern imaging and combined modality therapies (surgery, chemotherapy and radiation therapy).

Entities:  

Keywords:  extended field radiation; locally advanced cervical cancer; para-aortic nodal metastases

Mesh:

Year:  2015        PMID: 25591841     DOI: 10.2217/fon.14.200

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

Review 1.  The role of para-aortic nodal irradiation in cervical cancer.

Authors:  Adela Poitevin Chacón; Jessica Chavez-Nogueda; Rubí Ramos-Prudencio; Michelle Aline Villavicencio-Queijeiro; Francisco Lozano-Ruiz
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-09

2.  Roles of posttherapy 18F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy.

Authors:  Feng-Yuan Liu; Tzu-Pei Su; Chun-Chieh Wang; Angel Chao; Hung-Hsueh Chou; Yu-Chen Chang; Tzu-Chen Yen; Chyong-Huey Lai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-22       Impact factor: 9.236

3.  Therapeutic value of surgical paraaortic staging in locally advanced cervical cancer: a multicenter cohort analysis from the FRANCOGYN study group.

Authors:  Yohann Dabi; Vanille Simon; Xavier Carcopino; Sofiane Bendifallah; Lobna Ouldamer; Vincent Lavoue; Geoffroy Canlorbe; Emilie Raimond; Charles Coutant; Olivier Graesslin; Pierre Collinet; Alexandre Bricou; Emile Daraï; Cyrille Huchon; Marcos Ballester; Bassam Haddad; Cyril Touboul
Journal:  J Transl Med       Date:  2018-11-26       Impact factor: 5.531

4.  Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.

Authors:  Simone Marnitz; Audrey Tieko Tsunoda; Peter Martus; Marcelo Vieira; Renato Jose Affonso Junior; João Nunes; Volker Budach; Hermann Hertel; Alexander Mustea; Jalid Sehouli; Jens-Peter Scharf; Uwe Ulrich; Andreas Ebert; Iris Piwonski; Christhardt Kohler
Journal:  Int J Gynecol Cancer       Date:  2020-12       Impact factor: 3.437

5.  Cost-Effectiveness Analysis of Diagnostic Tests for Para-Aortic Lymph Node Detection in Locally Advanced Cervical Cancer.

Authors:  Kanyarat Katanyoo; Usa Chaikledkaew; Montarat Thavorncharoensap; Arthorn Riewpaiboon
Journal:  Clinicoecon Outcomes Res       Date:  2021-11-22

6.  Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases.

Authors:  Xiaotian Han; Hao Wen; Xingzhu Ju; Xiaojun Chen; Guihao Ke; Yuqi Zhou; Jin Li; Lingfang Xia; Jia Tang; Shanhui Liang; Xiaohua Wu
Journal:  Oncotarget       Date:  2017-03-08

7.  Patterns of lymph node metastasis in locally advanced cervical cancer.

Authors:  Zhikai Liu; Ke Hu; An Liu; Jie Shen; Xiaorong Hou; Xin Lian; Shuai Sun; Junfang Yan; Fuquan Zhang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.